An expanded access record providing BMN 110 in Mucopolysaccharidosis IVA, Morquio A Syndrome and MPS IVA, sponsored by BioMarin Pharmaceutical. Approved for marketing at 25 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-04-02.
Sponsored by BioMarin Pharmaceutical · Expanded access
The Expanded Access Program (EAP) is an open-label, multicenter program to:
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.
145 studies on the registry are indexed under Mucopolysaccharidoses; 11 are open to participants now.
Browse Mucopolysaccharidoses studies →BioMarin Pharmaceutical is the lead sponsor of 110 studies on the registry; 13 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioMarin Pharmaceutical